MX2022011372A - Composiciones de zinc-y-pga y metodos para tratar el cancer. - Google Patents
Composiciones de zinc-y-pga y metodos para tratar el cancer.Info
- Publication number
- MX2022011372A MX2022011372A MX2022011372A MX2022011372A MX2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A MX 2022011372 A MX2022011372 A MX 2022011372A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- tumors
- compositions
- zinc
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920002643 polyglutamic acid Polymers 0.000 abstract 2
- 206010061968 Gastric neoplasm Diseases 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical class [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008297 liquid dosage form Substances 0.000 abstract 1
- 208000037841 lung tumor Diseases 0.000 abstract 1
- 230000000955 neuroendocrine Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 208000025421 tumor of uterus Diseases 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a composiciones farmacéuticas que comprenden una sal de zinc2+ y un vehículo de ácido ?-poliglutámico y, opcionalmente, un inhibidor de NF-?B como agente de sensibilización de tumor, y a métodos para usar tales composiciones para tratar tumores en pacientes. Los métodos incluyen administrar una forma de dosis líquida o una forma de dosis sólida de una cantidad terapéuticamente eficaz de una sal de Zn(II) y un vehículo de ácido ?-poliglutámico a un paciente que lo requiera. Se proveen métodos de tratamiento de un amplio espectro de tumores humanos que incluyen tumores con un fenotipo resistente a fármaco usando las composiciones divulgadas. Los tumores que responden a las composiciones farmacéuticas aquí divulgadas incluyen tumores neuroendocrinos (neuroblastoma), gástricos, uterinos y pulmonares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201609131YA SG10201609131YA (en) | 2016-11-01 | 2016-11-01 | Zinc-pga compositions and methods for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011372A true MX2022011372A (es) | 2022-10-10 |
Family
ID=60327362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005104A MX2019005104A (es) | 2016-11-01 | 2017-10-31 | Composiciones de zinc-y-pga y métodos para tratar el cancer. |
MX2022011372A MX2022011372A (es) | 2016-11-01 | 2019-04-30 | Composiciones de zinc-y-pga y metodos para tratar el cancer. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005104A MX2019005104A (es) | 2016-11-01 | 2017-10-31 | Composiciones de zinc-y-pga y métodos para tratar el cancer. |
Country Status (10)
Country | Link |
---|---|
US (1) | US11944640B2 (es) |
EP (1) | EP3534914A1 (es) |
JP (2) | JP7083835B2 (es) |
KR (1) | KR102616690B1 (es) |
CN (2) | CN108014131B (es) |
AU (2) | AU2017354787B2 (es) |
CA (1) | CA3042383A1 (es) |
MX (2) | MX2019005104A (es) |
SG (3) | SG10201609131YA (es) |
WO (1) | WO2018084806A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
SG10201708886RA (en) * | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
EP3810154A1 (en) * | 2018-06-22 | 2021-04-28 | Xylonix Pte. Ltd. | Oncology treatments using zinc agents |
KR102094182B1 (ko) * | 2018-06-28 | 2020-03-30 | 주식회사 알랙스탠드 | 아연 함유 수용성 폴리글루타믹산 복합체 조성물 |
JP2024510327A (ja) | 2021-03-18 | 2024-03-06 | ジロニックス・ピーティーイー.リミテッド | 医薬ポリマーコンジュゲート |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2897122A (en) | 1956-10-04 | 1959-07-28 | Frosst & Co Charles E | Enteric coated product |
JP2712583B2 (ja) | 1989-06-28 | 1998-02-16 | 味の素株式会社 | 易吸収性ミネラル含有飲食物 |
JP3551149B2 (ja) | 1992-03-24 | 2004-08-04 | 味の素株式会社 | 易吸収性ミネラル含有組成物及びそれを含有する飲食品 |
EP0605757B1 (en) | 1992-11-25 | 2001-08-16 | Ajinomoto Co., Inc. | Compositions and goods containing minerals and poly-gamma-glutamic acid |
US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
ITMI950515A0 (it) | 1995-03-16 | 1995-03-16 | Valpharma Sa | Formulazioni gastroresistenti contenenti zinco |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
JPH11313618A (ja) | 1998-05-06 | 1999-11-16 | Yoshio Inoue | 胃にやさしい家畜用ミネラル(亜鉛)製剤及びその製造法 |
CA2395191A1 (en) | 1999-12-23 | 2001-06-28 | Tedman Ehlers | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
US20020061599A1 (en) | 1999-12-30 | 2002-05-23 | Elling Christian E. | Method of identifying ligands of biological target molecules |
AU2003232884A1 (en) | 2002-01-25 | 2003-09-02 | Emory University | Solenopsin a, b and analogs as novel angiogenesis inhibitors |
WO2004080210A1 (en) | 2003-03-14 | 2004-09-23 | Boehringer Ingelheim Danmark A/S | Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea |
KR100498812B1 (ko) | 2003-07-10 | 2005-07-01 | 주식회사 바이오리더스 | 초고분자량의 폴리감마글루탐산을 함유하는 미네랄의 체내흡수 촉진용 조성물 |
JP4457641B2 (ja) | 2003-11-10 | 2010-04-28 | 味の素株式会社 | ゼラチンカプセル |
JP5162812B2 (ja) | 2004-07-08 | 2013-03-13 | 大正製薬株式会社 | 亜鉛含有経口投与用組成物 |
CN103735560A (zh) | 2005-06-07 | 2014-04-23 | 耶鲁大学 | 使用克来夫定和替比夫定治疗癌症和其它病症或疾病状态的方法 |
CA2612979A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
JPWO2007043606A1 (ja) * | 2005-10-12 | 2009-04-16 | 株式会社ジェノラックBl | アニオン性ポリアミノ酸/金属複合体からなる抗糖尿病薬剤 |
WO2007109290A2 (en) | 2006-03-20 | 2007-09-27 | Pharmacyclics, Inc. | Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer |
CN101674852A (zh) | 2007-04-10 | 2010-03-17 | 日东电工株式会社 | 多功能聚谷氨酸盐药物载体 |
EP2155253A2 (en) | 2007-05-09 | 2010-02-24 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
AU2008251836A1 (en) | 2007-05-09 | 2008-11-20 | Salutria Pharmaceuticals, Llc | Spiro compounds for treatment of inflammatory disorders |
AU2009344184B2 (en) | 2009-04-10 | 2016-05-12 | Cypress Pharmaceuticals, Inc. | Phosphate-binding magnesium salts and uses thereof |
JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
CN101716180B (zh) | 2009-11-06 | 2013-04-24 | 广西强寿药业集团有限公司 | 一种组合补充锌、钙药物及其制备方法 |
US20110117210A1 (en) | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
US9211258B2 (en) | 2010-03-10 | 2015-12-15 | Lupin Limited | Rifaximin ready-to-use suspension |
ES2627820T3 (es) | 2011-09-13 | 2017-07-31 | Pharmacyclics, Inc. | Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas |
JP6121556B2 (ja) | 2012-11-21 | 2017-04-26 | ケイビーエス リサーチ、 エルエルシー | ハーブサプリメントおよびその使用の方法 |
TWI660748B (zh) | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦(Tolvaptan)的懸浮液 |
WO2014155142A1 (en) * | 2013-03-28 | 2014-10-02 | Bbs Nanotechnology Ltd. | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it |
JP2016516781A (ja) | 2013-04-12 | 2016-06-09 | ネッド バイオシステムズ, インコーポレイテッド | 癌治療 |
JP6262334B2 (ja) | 2013-04-26 | 2018-01-17 | 日東電工株式会社 | ポリ(グルタミル−グルタマート)結合体を製造するための大規模な方法 |
US10398682B2 (en) | 2013-07-15 | 2019-09-03 | The Board Of Regents Of The University Of Texas System | Methods and compositions to prevent or treat bacterial infections |
JP2016069303A (ja) | 2014-09-29 | 2016-05-09 | タカラバイオ株式会社 | フコイダンを有効成分とする脱毛抑制用組成物 |
EP3006045B3 (en) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
AU2015330937B2 (en) | 2014-10-08 | 2021-07-15 | Theriva Biologics, Inc. | Beta-lactamase formulations and uses thereof |
US20160122739A1 (en) | 2014-10-31 | 2016-05-05 | Wisconsin Alumni Research Foundation | Factor ix variants and methods of use therefor |
WO2016088816A1 (ja) | 2014-12-03 | 2016-06-09 | ノーベルファーマ株式会社 | 酢酸亜鉛水和物錠及びその製造方法 |
EA201990530A1 (ru) | 2016-08-19 | 2019-07-31 | БРУКЛИН ИММУНОТЕРАПЬЮТИКС ЭлЭлСи | Пути применения ингибиторов pd-1/pd-l1 и/или ингибиторов ctla-4 с биологическим средством, содержащим несколько цитокиновых компонентов, для лечения рака |
SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
SG10201708886RA (en) | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
EP3810154A1 (en) | 2018-06-22 | 2021-04-28 | Xylonix Pte. Ltd. | Oncology treatments using zinc agents |
-
2016
- 2016-11-01 SG SG10201609131YA patent/SG10201609131YA/en unknown
-
2017
- 2017-10-31 EP EP17798014.1A patent/EP3534914A1/en active Pending
- 2017-10-31 AU AU2017354787A patent/AU2017354787B2/en active Active
- 2017-10-31 WO PCT/SG2017/050545 patent/WO2018084806A1/en unknown
- 2017-10-31 JP JP2019545869A patent/JP7083835B2/ja active Active
- 2017-10-31 CA CA3042383A patent/CA3042383A1/en active Pending
- 2017-10-31 US US16/346,286 patent/US11944640B2/en active Active
- 2017-10-31 SG SG11201903753QA patent/SG11201903753QA/en unknown
- 2017-10-31 MX MX2019005104A patent/MX2019005104A/es unknown
- 2017-10-31 KR KR1020197015744A patent/KR102616690B1/ko active IP Right Grant
- 2017-10-31 SG SG10202013112YA patent/SG10202013112YA/en unknown
- 2017-11-01 CN CN201711108631.5A patent/CN108014131B/zh active Active
- 2017-11-01 CN CN202310311382.9A patent/CN116350658A/zh active Pending
-
2019
- 2019-04-30 MX MX2022011372A patent/MX2022011372A/es unknown
-
2022
- 2022-06-01 JP JP2022089345A patent/JP7466822B2/ja active Active
-
2023
- 2023-05-23 AU AU2023203220A patent/AU2023203220A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7466822B2 (ja) | 2024-04-15 |
AU2023203220A1 (en) | 2023-06-22 |
SG10201609131YA (en) | 2018-06-28 |
SG10202013112YA (en) | 2021-02-25 |
KR102616690B1 (ko) | 2023-12-21 |
SG11201903753QA (en) | 2019-05-30 |
US11944640B2 (en) | 2024-04-02 |
JP2022116255A (ja) | 2022-08-09 |
EP3534914A1 (en) | 2019-09-11 |
CN108014131A (zh) | 2018-05-11 |
CN116350658A (zh) | 2023-06-30 |
AU2017354787B2 (en) | 2023-02-23 |
KR20190120159A (ko) | 2019-10-23 |
WO2018084806A1 (en) | 2018-05-11 |
JP7083835B2 (ja) | 2022-06-13 |
AU2017354787A1 (en) | 2019-05-16 |
US20190255104A1 (en) | 2019-08-22 |
CA3042383A1 (en) | 2018-05-11 |
CN108014131B (zh) | 2023-04-14 |
JP2019534330A (ja) | 2019-11-28 |
MX2019005104A (es) | 2019-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
MX2019012884A (es) | Terapia de combinacion. | |
IN2015DN00376A (es) | ||
MX2016016744A (es) | Inhibidores de ezh2 para tratar linfomas. | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
PH12016502352A1 (en) | Pharmaceutical composition | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
PH12020500666A1 (en) | Pladienolide compounds and their use | |
MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
SG10201708886RA (en) | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
MX2019001210A (es) | Composicion farmaceutica anticancer. | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
EA202091908A3 (ru) | Комбинированная терапия для лечения онкологического заболевания |